Ftse Mib
34.608,59
-0,62%
DAX
18.726,76
-0,21%
S&P 500
5.310,79
0,05%
NASDAQ
16.784,21
-0,06%
Bitcoin
69.855,74
-2,24%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Dare Bioscience Inc (DARE) Dare Bioscience Inc (DARE) Notizie

DARE

Dare Bioscience (DARE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DARE
DataOraFonteTitoloSimboloCompagnia
14/05/202422:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DAREDare Bioscience Inc
14/05/202414:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
14/05/202414:00GlobeNewswire Inc.Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company UpdateNASDAQ:DAREDare Bioscience Inc
13/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DAREDare Bioscience Inc
10/05/202422:12Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DAREDare Bioscience Inc
07/05/202414:00GlobeNewswire Inc.Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024NASDAQ:DAREDare Bioscience Inc
02/05/202414:00GlobeNewswire Inc.Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke NetworkNASDAQ:DAREDare Bioscience Inc
30/04/202413:30GlobeNewswire Inc.Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key CatalystsNASDAQ:DAREDare Bioscience Inc
23/04/202414:00GlobeNewswire Inc.Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1NASDAQ:DAREDare Bioscience Inc
11/04/202414:00GlobeNewswire Inc.Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal ContraceptiveNASDAQ:DAREDare Bioscience Inc
28/03/202413:00GlobeNewswire Inc.Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company UpdateNASDAQ:DAREDare Bioscience Inc
28/03/202412:42IH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:DAREDare Bioscience Inc
21/03/202413:00GlobeNewswire Inc.Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024NASDAQ:DAREDare Bioscience Inc
22/02/202414:00GlobeNewswire Inc.Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual MeetingNASDAQ:DAREDare Bioscience Inc
31/01/202414:00GlobeNewswire Inc.Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024NASDAQ:DAREDare Bioscience Inc
29/01/202422:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DAREDare Bioscience Inc
26/01/202422:30GlobeNewswire Inc.Daré Bioscience Announces Executive Team and Board of Directors ChangesNASDAQ:DAREDare Bioscience Inc
17/01/202414:00GlobeNewswire Inc.Daré Bioscience Announces Grant to Support Biotherapeutic Product DevelopmentNASDAQ:DAREDare Bioscience Inc
04/01/202414:00GlobeNewswire Inc.Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of DiseasesNASDAQ:DAREDare Bioscience Inc
26/12/202322:05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:DAREDare Bioscience Inc
26/12/202314:00GlobeNewswire Inc.Daré Bioscience Secures $12 million in Royalty-backed Investment StructureNASDAQ:DAREDare Bioscience Inc
20/12/202314:00GlobeNewswire Inc.Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical StudyNASDAQ:DAREDare Bioscience Inc
13/12/202314:00GlobeNewswire Inc.Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical StudyNASDAQ:DAREDare Bioscience Inc
07/12/202314:00GlobeNewswire Inc.Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with MenopauseNASDAQ:DAREDare Bioscience Inc
04/12/202314:00GlobeNewswire Inc.Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal ContraceptiveNASDAQ:DAREDare Bioscience Inc
20/11/202314:00GlobeNewswire Inc.Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health ProgramsNASDAQ:DAREDare Bioscience Inc
13/11/202314:00GlobeNewswire Inc.Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific MeetingNASDAQ:DAREDare Bioscience Inc
09/11/202314:00GlobeNewswire Inc.Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company UpdateNASDAQ:DAREDare Bioscience Inc
06/11/202314:00GlobeNewswire Inc.Daré Bioscience to Participate in Three November ConferencesNASDAQ:DAREDare Bioscience Inc
02/11/202313:00GlobeNewswire Inc.Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023NASDAQ:DAREDare Bioscience Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DARE

La tua Cronologia

LSE
LCG
London Capital Hldgs
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network